Glaxosmithkline Pharmaceuticals Ltd vs Titan Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2349 as of 04 May 11:10 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Titan Biotech Ltd changed from 5.1 on March 2021 to 16.2 on March 2025 . This represents a CAGR of 26.01% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Titan Biotech Ltd changed from ₹ 153.33 crore on March 2021 to ₹ 348.36 crore on March 2025 . This represents a CAGR of 17.84% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Titan Biotech Ltd for the Dec '25 is ₹ 57.76 crore as compare to the Sep '25 revenue of ₹ 55.68 crore. This represent the growth of 3.74% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Titan Biotech Ltd for the Dec '25 is ₹ 12.09 crore as compare to the Sep '25 ebitda of ₹ 10.65 crore. This represent the growth of 13.52% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Titan Biotech Ltd changed from ₹ 5.7 crore to ₹ 7.87 crore over 7 quarters. This represents a CAGR of 20.24% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Titan Biotech Ltd changed from 4.31 % on March 2021 to 9.04 % on March 2025 . This represents a CAGR of 15.97% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Titan Biotech Ltd

Titan Biotech Limited, the New Delhi based company is into manufacture of Biological Peptones, Extracts and Dehydrated Culture media which are very conducive for the growth of micro organisms.
They are primarily used in the development and growth of micro organisms in clinical diagnosis production of vaccines antibiotics antisera etc, Checking the sensitivity of antibiotics in pharmaceutical industry, checking the bacterial contamination in food & water, tissue culture laboratories and in the departments of microbiology & botony in medical colleges/universities. The company uses Meat, Bile, Pancreatic, Liver, Blood, Brain, Heart and other parts of animals sourced from slaughter house and other vegetable products like soya, casein etc. converting them into free flowing powder to produce Peptones, Extracts and Hydrolysates which are further used in manufacturing of Dehydrated Culture Media and as raw material in pharma health products and other industries.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Titan Biotech Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Titan Biotech Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,566 Cr while Market cap of Titan Biotech Ltd is 2,049 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Titan Biotech Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Titan Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Titan Biotech Ltd?

As of May 4, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2335.6. On the other hand, Titan Biotech Ltd stock price is INR ₹496.0.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Titan Biotech Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Titan Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.